Continuing medical educationWhat's new: Management of venous leg ulcers: Approach to venous leg ulcers
Introduction
Leg ulcers are a common problem, with an estimated prevalence of 1% to 2% in the adult population, similar to the prevalence of psoriasis and alopecia areata.1, 2, 3 With shifting demographics toward an aging population, sedentary lifestyles, an increased prevalence of obesity, and the emergence of various chronic diseases, leg ulcers will likely continue to be a significant burden on the health care system.4, 5 Despite the myriad potential causes of leg ulcers, a majority are caused by vascular abnormalities, with venous disease being the most common cause. Recent advances in the diagnosis and treatment of leg ulcers combined with the latest available evidence indicate a need for an update on this topic. A systematized approach and the judicious use of advanced expensive therapeutics are critical. The aim of this continuing medical education article is to provide an update on venous leg ulcers (VLUs). Part I is focused on the diagnostic approach to VLUs. In part II, the current medical and surgical management options will be reviewed.
Section snippets
Epidemiology
Key points Approximately 1.5 to 3 per 1000 adults have active leg ulcers in North America Venous leg ulcers are more common in elderly patients, but 22% of individuals develop their first venous leg ulcers by 40 years of age, and 13% by 30 years of age
The overall incidence of venous disease has been documented to be 76.1 per 100,000 person-years.6 It is estimated that approximately 1.5 to 3 per 1000 North American adults have active leg ulcers.7 Although chronic leg ulcers may be caused by many
Pathogenesis of venous disease
Key point Valve dysfunction, outflow obstruction, arteriovenous malformation, and calf muscle pump failure contribute to the pathogenesis of venous disease
The venous system is constructed like a ladder, with deep and superficial veins forming the 2 sides connected by perforator veins as the rungs (Fig 1). The calf muscle pump acts as a “peripheral heart,” propelling venous blood toward the heart during calf muscle pump contraction. Unidirectional valves in the vein allow blood flow in 1 direction toward
Approach to venous leg ulcers
Key points A comprehensive history and physical examination are essential in the evaluation of chronic venous insufficiency and ulceration Varicose veins in the medial thigh and calf may implicate involvement of the great saphenous vein; dilated veins in the anterolateral thigh and knee are related to anterior saphenous insufficiency
A comprehensive history and physical examination are required for an accurate diagnosis (Fig 6). Information should include symptoms, exacerbating and alleviating factors,
Vascular assessment: Arterial and venous
After a comprehensive clinical assessment, subsequent noninvasive and sometimes invasive investigations may be indicated to confirm the diagnosis and plan treatment options. Assessment of the arterial system to rule out mixed arteriovenous disease is important. Up to 25% of patients with a VLU have concomitant peripheral arterial disease.59, 60
References (70)
- et al.
Psoriasis: epidemiology
Clin Dermatol
(2007) - et al.
Nutritional status and wound severity of overweight and obese patients with venous leg ulcers: a pilot study
J Vasc Nurs
(2008) - et al.
Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based study
J Vasc Surg
(2001) - et al.
Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France
J Vasc Surg
(2004) - et al.
The epidemiology of chronic venous insufficiency and varicose veins
Ann Epidemiol
(2005) - et al.
Risk factors for chronic venous insufficiency: a dual case-control study
J Vasc Surg
(1995) - et al.
Incidence of and risk factors for iliocaval venous obstruction in patients with active or healed venous leg ulcers
J Vasc Surg
(2011) - et al.
Does inflammation have a role in the pathogenesis of venous ulcers? A critical review of the evidence
J Invest Dermatol
(2011) - et al.
The “trap” hypothesis of venous ulceration
Lancet
(1993) - et al.
A gene signature of nonhealing venous ulcers: potential diagnostic markers
J Am Acad Dermatol
(2008)
Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing
Am J Pathol
Which venous leg ulcers will heal with limb compression bandages?
Am J Med
Dermatologic complications of chronic venous disease: medical management and beyond
Ann Vasc Surg
Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease
J Vasc Surg
The prevalence of thrombophilia in patients with chronic venous leg ulceration
J Vasc Surg
Evaluation of varicose veins: what do the clinical signs and symptoms reveal about the underlying disease and need for intervention?
Semin Vasc Surg
Reliability of electronic versus manual wound measurement techniques
Arch Phys Med Rehabil
Surrogate endpoints for the treatment of venous leg ulcers
J Invest Dermatol
Histopathologic analysis of dermal lymphatic alterations in chronic venous insufficiency ulcers using D2-40
J Am Acad Dermatol
Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery (R) and the American Venous Forum
J Vasc Surg
Ease of use, feasibility and performance of ankle arm index measurement in patients with chronic leg ulcers. Study of 100 consecutive patients
J Mal Vasc
The accuracy of the physical examination for the detection of lower extremity peripheral arterial disease
Can J Cardiol
A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life
J Am Coll Cardiol
Risk factors associated with the failure of a venous leg ulcer to heal
Arch Dermatol
An audit of leg and foot ulcer care in an Ontario community care access centre
Wound Care Canada
A transprofessional comprehensive assessment model for persons with lower extremity leg and foot ulcers
Wound Care Canada
Socioeconomic impact of chronic venous insufficiency and leg ulcers
Angiology
ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)
Eur Heart J
Atypical ulcers: wound biopsy results from a university wound pathology service
Ostomy Wound Manage
Venous leg ulcer: incidence and prevalence in the elderly
J Am Acad Dermatol
Chronic venous disease in an ethnically diverse population: the San Diego Population Study
Am J Epidemiol
Prolonged standing at work and hospitalisation due to varicose veins: a 12 year prospective study of the Danish population
Occup Environ Med
Pain and health-related quality of life in people with chronic leg ulcers
Chronic Dis Inj Can
Investigation of chronic venous insufficiency: a consensus statement (France, March 5-9, 1997)
Circulation
Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial
BMJ
Cited by (84)
Ultrasound evaluation of lower extremity chronic venous disease
2022, Venous Ulcers, Second EditionEvaluation of timolol maleate gel for management of hard-to-heal chronic venous leg ulcers. Phase II randomised-controlled study
2021, Annales de Dermatologie et de VenereologiePrevention strategies for the recurrence of venous leg ulcers: A scoping review
2024, International Wound JournalAssociation between stroke and venous leg ulcers: A Mendelian randomization study
2024, International Wound JournalAn Evidence Map of Clinical Practice Guideline Recommendations and Quality on Venous Leg Ulcer
2024, Advances in Wound CareSummary of the best evidence for physical activity in patients with venous leg ulcer
2024, Chinese Journal of Nursing
Funding sources: None.
Dr Kirsner is an advisory board member of 3M, KCI, Keraplast, Kerecis, and Mölnlycke, and is an investigator for Macrocure and Smith & Nephew. Dr Margolis is an advisory board member of Kerecis. Dr Alavi is an advisory board member for AbbVie, Janssen; an investigator for AbbVie, Novartis, and Xoma; and received a grant from AbbVie. The other authors have no conflicts of interest to declare.
Date of release: April 2016
Expiration date: April 2019